Release Date: April 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What is the sustainable level of income tax credits or R&D tax credits for Evotec, and are there any risks to these credits? A: Paul Hitchin, CFO, stated that the tax credits are expected to grow in line with business growth and where R&D work is performed. Currently, there are no perceived risks to these credits.
Q: Can you provide more details about the composition of Evotec's drug portfolio, specifically the phase composition of the 100 products? A: Cord Dohrmann, Chief Scientific Officer, explained that there are six assets in clinical stages and six in preclinical stages. Over the next 24 months, about 15 assets have the potential to move from preclinical to clinical stages.
Q: How sophisticated are the models for phasing out animal testing, and is it possible to eliminate animal testing in the foreseeable future? A: Cord Dohrmann noted that Evotec is well-positioned to support the FDA's initiative to phase out animal testing. The company has developed advanced human microphysiological systems and AI-based approaches, which are expected to significantly improve predictive accuracy.
Q: What are the growth drivers for Just - Evotec Biologics over the next 12 to 18 months, and how de-risked are these drivers? A: Christian Wojczewski, CEO, mentioned that there is high confidence in the growth of Just - Evotec Biologics due to pre-commitments from partners like Sandoz and a strong customer base developed over the last two years.
Q: What is the synergy between Evotec's divisions, and what was the rationale for owning these businesses? A: Christian Wojczewski explained that the synergy lies in technology and science leadership, enabling partners to succeed. Shared R&D focuses on small molecules, while Just - Evotec Biologics focuses on large molecules, both leveraging technology to enhance partner success.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.